- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00985907
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma (DMV)
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2
Adjunctive therapy with a bisphosphonate, either pamidronate or zoledronic acid, will be given monthly.
Dose Escalation Schedule: Dose escalation will occur only after patients have completed at least two cycles at a given dose level.
- If 0/3 experience DLT (as defined in attachment Section 6.0), the next three patients will be escalated by one dose level.
If 1/3 experience DLT, 3 additional patients enrolled at this dose level.
- If 0, 1, or 2 of these additional patients experience DLT (i.e. total 3/6), the dose will be escalated.
- If 3/3 experience DLT (i.e. total 4/6) then the next lower dose will be considered the MTD..
If 2/3 experience DLT, 3 additional patients enrolled at this dose level.
- If 0 or 1 of these additional patients experience DLT (i.e. total 3/6), the dose will be escalated.
- If 2 or more/3 experience DLT (i.e. total more than 3/6) then the next lower dose level is MTD
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
New York
-
New York, New York, United States, 10011
- St. Vincent's Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Disease Characteristics:
- Patient previously diagnosed with multiple myeloma; Durie-Salmon Stage I, II, or III based on standard criteria
- Progressive disease. For non-secretory multiple myeloma, progressive disease is defined as bone marrow biopsy with > 25% increase in plasma cells or an absolute increase of at least 10% over prior known level. Alternatively, development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium >11.5 mg/dL), or relapse from complete response.
Patient Characteristics:
- 18 yrs or older
- Patient has given voluntary written informed consent.
- Unless post-menopausal or surgically sterilized, a female must be willing to use an acceptable method of birth control
- Male patient must agree to use an acceptable method for contraception for the duration of the study.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
- Life expectancy is at least 3 months.
• Absolute Neutrophil Count (ANC) over 1,000/ul without the use of colony stimulating factors
- Platelets over 50,000/ul without transfusion support 7 days
- Bilirubin 2.0 mg/dl or less
- aspartate aminotransferase (AST) 4 times or less upper limit normal Prior Therapy for Multiple Myeloma: Patients must have had at least 2 prior therapeutic regimens
Exclusion Criteria:
- Pregnant or breast feeding
- History of allergic reaction to compounds containing boron or mannitol.
- Active uncontrolled viral (including HIV), bacterial, or fungal infection.
- Grade III or IV toxicity due to previous anti-neoplastic therapy
- More than Grade 2 motor or sensory neuropathy
- Myocardial infarction within 6 months of enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled arrhythmias, or electrocardiographic evidence of acute ischemia.
- For any patients whose lifetime cumulative doxorubicin dose exceeds 400mg/m2, patients with left ventricular ejection fraction (LVEF) less than 35% by multigated acquisition (MUGA) .
- Concurrent administration of liposomal doxorubicin, melphalan, and bortezomib (single or two drug combinations of these are permissible)
- Less than 3 weeks since most recent chemotherapy or concurrent chemotherapy
- Use of corticosteroids (mroe than 10 mg prednisone/day or equivalent)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Doxil® + Melphalan + Velcade (DMV)
|
Doxil®: IV over 30-60 min, Day 1 q28d Melphalan: IV over 30 min, Day 1 q28d Velcade®: IV bolus, Day 1, 4, 8, 11 q28d Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2 Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2 Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2 Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Dose Limiting Toxicities (DLT) (Phase 1)
Time Frame: Up to 2 cycles of treatment, approximately 56 days
|
Safety assessments will be evaluated as the proportion of patients experiencing the following: treatment-related grade 3 or higher toxicity (hematologic and nonhematologic) and treatment-related death.
|
Up to 2 cycles of treatment, approximately 56 days
|
Maximum Tolerated Dose (MTD) (Phase 1)
Time Frame: Up to 1 year
|
The MTD will be considered the dose below where <= 3 patients experience a DLT and the dose that two cycles can be given without meeting toxicity criteria.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of All Treatment-related Toxicities at the MTD (Phase 1)
Time Frame: 5 years
|
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3 will be used to determine all treatment related toxicities at the MTD.
Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
|
5 years
|
Overall Response Rate
Time Frame: Up to 5 years
|
At each cycle, participants will be assessed for treatment response: Complete Response (CR), Near CR(nCR), Partial Response (PR), Minimal Response (MR), Stable Disease (SD), or Progressive Disease (PD) on at least 2 measurements at minimum of a 4 week interval.
The overall response rate will use the best response of CR, nCR, PR, MR, or SD.
In order to qualify for responses, the following events may NOT have occurred - new/increased size of plasmacytomas or bone lesions, recurrence or persistence of hypercalcemia.
Collapse of bony structure from previous disease will not constitute progression or failure to respond.
Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
|
Up to 5 years
|
Time to Response (Phase 2)
Time Frame: 28 days
|
Efficacy of DMV as determined by time to first observed response.
Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
|
28 days
|
Progression-free Survival (Phase 2)
Time Frame: Up to 5 years
|
Efficacy of DMV as determined by progression free survival.
Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
|
Up to 5 years
|
Overall Survival (Phase 2)
Time Frame: Up to 5 years
|
Overall survival is defined as the amount of time from start of study therapy until death, or study completion.
Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis
|
Up to 5 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antibiotics, Antineoplastic
- Melphalan
- Bortezomib
- Liposomal doxorubicin
Other Study ID Numbers
- 04262
- NCI-2011-01238 (Registry Identifier: University of California, San Francisco)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Doxil, melphalan, bortezomib
-
University of California, San FranciscoWithdrawn
-
Uppsala UniversityDalarna County Council, Sweden; Uppsala County Council, SwedenNot yet recruitingMyeloma Multiple
-
University Hospital, ToulouseMinistry of Health, France; Janssen, LPCompletedMultiple MyelomaFrance, Belgium
-
Dartmouth-Hitchcock Medical CenterMillennium Pharmaceuticals, Inc.CompletedMyelodysplastic Syndromes | Acute Myelogenous LeukemiaUnited States
-
Boston Medical CenterCompletedMultiple MyelomaUnited States
-
OncotherapeuticsCompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Janssen Research & Development, LLCCompletedMultiple MyelomaAustralia, France, Poland, United Kingdom, United States, Spain, Israel, Portugal, South Africa, Canada, Netherlands, Belgium, Singapore, Russian Federation, Czech Republic, Argentina, Austria
-
Hackensack Meridian HealthCompletedMultiple MyelomaUnited States
-
European Myeloma NetworkFondazione EMN Italy OnlusCompleted
-
Fondazione EMN Italy OnlusCompleted